Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine
Despite the importance of equitable representation in clinical trials, disparities persist with racial and ethnic minorities remaining largely underrepresented in trial populations. During the coronavirus disease 2019 (COVID-19) pandemic, wherein disease disproportionately affected racial and ethnic...
Main Authors: | Jameka Hill, Diane Montross, Melanie Ivarsson |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Public Health |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1113003/full |
Similar Items
-
Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine
by: Yoji Hoshina, et al.
Published: (2022-07-01) -
Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
by: Suresh Babu Chellapandian, et al.
Published: (2022-04-01) -
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
by: Daniele Focosi, et al.
Published: (2022-11-01) -
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
by: Angel Shabu, et al.
Published: (2023-12-01) -
Association Between Fever and Antibody Titer Trends After a Third Dose of the mRNA-1273 Vaccine
by: Naomi Matsumoto, et al.
Published: (2022-12-01)